Table 6.
Drugs that potentially target (modulate) proteins that interact with SARS CoV-2 proteins as described in reference [66]
| Entry | Viral Protein-(Human Gene) | Compound Name(s) |
|---|---|---|
| 1 | E protein-(BRD2/4) | JQ1,a RVX-208b |
| 2 | N protein-(CSNK2A2) | Silmitasertib (cancer),c TMCBa |
| 3 | NSP5-(HDAC2) | Apicidin,a Valproic acid (CNS disease, cancer)c |
| 4 | NSP6-(ATP6AP1) | Bafilomycin A1a |
| 5 | NSP6-(SIGMAR1) | E-52862,b PD-144418,a RS-PPCC,a PB28,a |
| Haloperidol (CNS disease)c | ||
| 6 | NSP6-(SLC6A15) | Loratadine (antihistamine)3 |
| 7 | ORF9C-(TMEM97) | PB28,a haloperidol (CNS disease)c |
| 8 | M protein-(ATP6V1A) | Bafilomycin A1a |
| 9 | NSP7-(COMT) | Entacapone (Parkinson’s disease)c |
| 10 | NSP7-(PTGES2) | Indomethacin (inflammation/pain)c |
| 11 | NSP7-(NDUFs) | Metformin (diabetes)c |
| 12 | ORF9C-(NDUFs) | Metforminc |
| 13 | NSP12-(RIPK1) | Ponatinib (cancer)c |
| 14 | NSP13-(PRKACA) | H-89a |
| 15 | NSP14-(IMPDH2) | Merimepodibb |
| 16 | NSP14-(GLA) | Migalastat (Fabry disease)c |
| 17 | NSP14-(IMPDH2) | Mycophenolic acid (organ rejection),3 ribavirin (virus)c |
| 18 | ORF8-(DNMT1) | Azacitidinec |
| 19 | ORF8-(LOX) | CCT 365623a |
| 20 | ORF9b-(MARK2/3) | Midostaurin,3 Ruxolitinibc |
| 21 | ORF9b-(DCTPP1) | ZINC1775962367,a ZINC4326719,a ZINC4511851a |
| 22 | ORF9b/NSP13-(MARK3/TBK1) | ZINC95559591a |
| 23 | ORF9C-(F2RL1) | AC-55541,a AZ8838a |
| 24 | ORF9C-(ABCC1) | Daunorubicinc |
| 25 | ORF9C-(F2RL1) | GB110a |
| 26 | ORF9C-(ABCC1) | S-Verapamil (hypertension)c |
| 27 | ORF9C-(F2RL1) | AZ3451a |
| 28 | M-Protein-(SLC1A3) | UCPH-101a |
| 29 | E protein-(BRD2/4) | ABBV-744,b dBET6,a MZ1,a CPI-0610b |
| 30 | N protein-(LARP1) | Sapanisertib,b Rapamycin (organ rejection)c |
| 31 | NSP2-(FKBP15) | Rapamycinc |
| 32 | ORF8-(FKBP7/10) | Rapamycinc |
| 33 | NSP2-(EIF4E2/H) | Zotatifinb |
| 34 | ORF10-(VCP) | CB5083b |
| 35 | NSP6-(SIGMAR1) | Chloroquine (malaria)c |
| 36 | NSP9-NEK9 | Dabrafenaib (cancer)c |
| 37 | NSP13-CEP250 | WDB002b |
| 38 | NSP14-IMPDH2 | Sanglifehrin Aa |
| 39 | ORF8-(FKBP7) | FK-506 (organ rejection)c |
| 40 | ORF8-(FKBP10) | FK-506c |
| 41 | ORF10-(CUL2) | Pevonedistatb |
| 42 | ORF10-(VCP) | DBeQ, ML240a |
| 43 | ORF8-(PLOD1/2) | Minoxidil (hair loss)c |
| 44 | NSP4/9/ORF6-(NUPs RAE1) | Selinexor (cancer)c |
Entries 1–28 were determined from chemoinformatics. Entries 29–44 were determined from specialist knowledge
aPre-clinical
bClinical trial
cFDA-approved drug. In parentheses after the drug is what the FDA-approved drug is used to treat in the clinic